hotspot -WSS

hotspot

author：explore 2025-09-06 03:50:46 - browse：14491

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Trump indictment: Who are the 'co

WSS

New safety details link Apellis eye drug to rare cases of blindness

The high personal cost of affirmative action for Black doctors

Physician groups backed by private equity giant lobby on mergers

Study: AI not yet building 'n

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Steward Health Care files for bankruptcy

Wikipedia

hotspot

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC wastewater surveillance dashboard to track bird flu hotspots

The high cost of giving birth even with insurance

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Jerome Adams on the need for new antivirals for Covid

‘Oppenheimer’ and the risks of AI in health care

Heart attack and stroke risk calculators need revising

Mitch McConnell episode has important public health takeaway

Apple is now the first public company to be valued at $3 trillion

Elevance, private equity launch primary care company

explore

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Telehealth startups turn to complex chronic diseases

explore

explore

Wikipedia

focus